Antimicrobial resistance, one of the world’s biggest killers, has reached an alarming tipping point.

Changing the way antibiotics are developed and accessed.

A public-health driven model to tackle AMR.

Our latest news and resources.

Protecting people from the rise and spread of drug-resistant infections.

Supporting efforts to ensure the right antibiotics are developed and reach the people who need them.

AMR Awareness Week: Public health needs to be bottom line

DownToEarth media coverage thumbnail

 

22 November 2023

Antimicrobial resistance (AMR) has been described as a silent pandemic. However, there is nothing silent about this escalating global crisis, which is now associated with nearly five million deaths a year, making it one of the world’s biggest killers.

New antibiotic treatments are urgently needed. But to stay ahead of drug-resistant bacteria, they also need to be the right antibiotics, those that have the greatest public health impact.

For that, a new antibiotic research and development (R&D) model is needed, one that ensures that the people most in need get access to these drugs, particularly in lower-income countries.